Qiagen Shares Rise on Acquisition Rumors | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Qiagen rose around 6 percent in Friday trade on the Nasdaq after rumors circulated in Europe that French drugmaker Sanofi-Aventis was mulling a €14.50 ($20.29) per share bid to acquire the firm.

Neither firm would comment on the rumors.

The rumored acquisition price represents a 26 percent premium over Qiagen's Thursday closing price of $16.05. In Friday afternoon trade, Qiagen's shares were up 6 percent at $17.01.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.